Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 23 for “"B cell malignancies"”.
-
Elucidating oncogenic mechanisms in human B cell malignancies
… two pieces of work investigating haematological malignancies; Acute Lymphoblastic Leukaemia (ALL) and Diffuse Large B Cell Lymphoma (DLBCL). Firstly, Pre-B ALL represents the most common paediatric malignancy and despite increasingly improved outcomes for patients, ~ 20% of all patients diagnosed …
-
ZFP36 proteins and mRNA targets in B cell malignancies
… and ZFP36 are able to degrade mRNAs of important cell regulators that include cytokines, cell signalling proteins and transcriptional factors. This project investigated two proposed targets for the protein family that have important roles in B cell biology, BCL2 and CD38 mRNAs. BCL2 is an …
-
Efficacy of Dual Cd19-Cd79B Car In B-Cell Malignancies
… responses, about 30%-60% of patients with B-cell malignancies relapse following CD19-targeting chimeric antigen receptor (CAR) T cell therapy. CD19 loss is a major cause of relapse and resistance after CD19 CAR T therapy. Dual antigen targeting could overcome resistance due to antigen escape …
-
The Role of Activation-Induced Cytidine Deaminase in Antibody Diversification and B Cell Malignancies
… (SHM) and class switch recombination (CSR) in B cells. SHM alters the affinity of an antibody for its corresponding antigen by introducing point mutations within the variable region of the immunoglobulin (Ig) gene heavy chain locus. CSR replaces the Ig μ constant region with one of the downstream …
-
Design, Development, Characterization and Testing of CD22 Targeted Long Circulating Liposomal Drug Delivery Systems for B Cell Malignancies
<p>Hematological malignances of the B cells affect almost 130,000 people in the United States every year of which approximately 44,000 lose their lives. Therapies for B cell malignancies such as doxorubicin, have limitations due to dose related adverse effects such as neutropenia and …
-
Tethered Il-15 to Augment The Therapeutic Potential of T Cells Expressing Chimeric Antigen Receptor: Maintaining Memory Potential, Persistence, and Antitumor Activity
… IL-15 to augment the therapeutic potential of T cells expressing chimeric antigen receptor: Maintaining memory potential, persistence, and antitumor activity</strong></p> <p>Adoptive immunotherapy can retarget T cells to CD19, a tumor-associated antigen (TAA) expressed on B-cell malignancies, by …
-
Investigating the role of PKC-β in tumour activated stromal cells
… chronic lymphocytic leukaemia (CLL) and other B-cell malignancies. However, a significant fraction of patients will relapse despite initial deep remissions. Studies have highlighted that the tumour microenvironment provides protective niches in which tumour cells receive survival signals …
-
Molecular Insights of Primary Thyroid B-cell Lymphomas by Somatic Genetic and Immunogenetic Profiling
… lymphoid tissue (EMZL) and diffuse large B-cell lymphoma (DLBCL), followed by follicular lymphoma (FL). The Du group has previously shown that thyroid EMZL has a distinct mutation profile, characterised by frequent and often concurrent deleterious mutations in *TET2* (86%), *TNFRSF14* (53%) …
-
Fc Gamma Receptors Facilitate Antigenic Modulation of LILRB4 and Function as Predictive Biomarkers in Acute Monocytic Leukemia
… chemotherapy as a bridge to hematopoietic stem cell transplant (HSCT). Even patients who achieve remission commonly relapse. This population of patients would greatly benefit from precision-targeted therapies but currently there are none approved for monocytic AML.</p> <p>Leukocyte …
-
Novel immunotherapy for paediatric cancers
… T lymphocytes to specific tumour antigens. CART cells targeting CD19 (CAR19) have demonstrated remarkable efficacy against B cell malignancies in clinic. Currently used methods of CAR gene transfer to T cells based on viral vectors are complicated by the time and expense involved in the elaborate …
-
Chimeric ANTI-CD19 Monoclonal Antibodies for the Treatment of Precursor B Cell Acute Lymphoblastic Leukemia
Thousands of people are diagnosed with B cell malignancies every year, yet the only FDA-approved immunotherapies for them are based on anti-CD20 monoclonal antibodies (MAbs). However, CD20 is not expressed on precursor B cell acute lymphoblastic leukemia (pre-B ALL), and CD20 expression is often …
-
Long-read transcriptome profiling of germinal centre B cells
… spliced genes are specific to immune cells, yet the regulation and function of AS during B cell activation remain largely unknown. The activation of naive B cells and the subsequent germinal centre (GC) reaction drive the cascade of reactions resulting in short- and long-term antibody …
-
A chromatin-modifying protein is a context-dependent modulator of cell survival in hematopoietic malignancies
… leukemia. Many genetic lesions in hematopoietic malignancies lead to altered function of one or more chromatin-modifying proteins, often resulting in less differentiated cells that are more therapy-resistant. While a number of these lesions have led to development of effective targeted therapies, …
-
Actions of Pi3K-Delta Inhibitor, Idelalisib, and Its Combination With Bendamustine In Chronic Lymphocytic Leukemia
… (α, β, δ, and γ) play a major role in cancer cell growth and survival. PI3K α and β are most studied. PI3K pathway is highly dysregulated in many cancers and aberrant PI3K signaling is associated with oncogene mutations and disease progression in solid tumors and in hematologic …
-
Épissage alternatif et mutations ponctuelles de Pax5 chez la leucémie lymphoîde chronique et les lymphomes de cellules B
The transcription factor Pax5, or B-cell Specific Activator Protein (BSAP), possesses oncogenic properties and its expression is often deregulated in certain cases of B-cell malignancies such as non-Hodgkin lymphoma and acute lyrnphoblastic leukemia. Recent studies have revealed that the Pax5 …
-
Cord Blood-Derived Invariant Natural Killer T Cells as a Platform for Allogeneic Chimeric Antigen Receptor Cell Therapy
<p>Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematopoietic malignancies achieving >50% complete response rates in numerous refractory/relapsed B cell malignancies. However, there are challenges that hinder CAR-T efficacy and bar the broader use of this therapy in …
-
Targeting and Reprogramming Tumor-Associated Macrophages with Polymeric Nanoparticle-Mediated mRNA Delivery for Cancer Treatment
… focal point of intense research, particularly B-cell malignancies, which are complex and drug-resistant. These malignancies arise from genetic changes and are influenced by the tumor microenvironment (TME), where tumor-associated macrophages (TAMs) play a key role. TAMs can be divided into …
-
Genomic investigation of primary immunodeficiency
… in the E3 ligase action of SOCS1, patient cells showed increased Toll-like receptor cytokine responses and hyperactivity of the Akt pathway. Thus, dysregulation of multiple immune pathways leads to autoimmunity and immunodeficiency in affected individuals. I then examined the functions and …
-
Revealing the role of Gα13 in germinal centre lymphomas
Diffuse large B cell lymphoma (DLBCL) and Burkitt lymphoma (BL) are aggressive B cell malignancies, arising from the transformation of germinal centre (GC) B cells. Although potentially curable with immuno-chemotherapy, 40% of DLBCL patient relapse and eventually succumb to their disease. In recent …
Page 1 of 2